David Wheeler is Professor of Kidney Medicine at University College London, UK, and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He trained in Birmingham, Cardiff and Boston, USA.

Professor Wheeler is a clinician scientist interested in the complications of chronic kidney disease (CKD), specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and delivery of several large-scale clinical trials testing lipid-lowering regimens (SHARP), calcimimetics (EVOLVE), intravenous iron (PIVOTAL), SGLT-2 inhibitors (CREDENCE and DAPA-CKD) and HIF stabilisers (ASCEND) in patients with CKD. He was co-chief investigator for the DAPA-CKD study.

Other roles include Honorary Professorial Fellow of the George Institute (Sydney, Australia) with a remit to support the organisation’s clinical trials activities in Europe. He has also been involved in the development of clinical practice guidelines for several organisations, including Kidney Disease: Improving Global Outcomes (KDIGO).

Professor Wheeler served as KDIGO co-chair between 2012 and 2019 and was also president of the UK Renal Association, chair of the UK Renal Registry and chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACTs) committee. He currently serves as the National Specialty Lead for the National Institute of Health Research Clinical Research Network.

Duality of interest: Professor Wheeler has received speaker’s honorarium / fees from Astra Zeneca and Astellas, and board member / advisory panel fees from Astra Zeneca and Astellas together with consultancy fees from Astra Zeneca and Astellas.

Date: Winter 2023